Stranica 1 iz 1002 rezultatima
The present application is a National Phase of International Application No. PCT/EP2005/011304 filed Oct. 20, 2005 and claims priority to German Patent Application No. 10 2004 054 215.5, filed Nov. 10, 2004. The contents of both applications are expressly incorporated herein by reference in their
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. national stage filing under 35 U.S.C. .sctn. 371(c), of International Application No. PCT/EP2015/061569, filed on May 26, 2015, which claims foreign priority of U.K. Patent Application No. 1409488.2, filed on May 28, 2014. The entire
This application incorporates a 502 KB text file named "seqlst00631" created Jul. 22, 2010, which is the sequence listing for this application.
TECHNICAL FIELD OF THE INVENTION
This invention is related to the area of cancer. In particular, it relates to diagnosis, prognosis, treatment, drug
TECHNICAL FIELD OF THE INVENTION
This invention is related to the area of cancer. In particular, it relates to diagnosis, prognosis, treatment, drug discovery, target discovery, clinical testing for cancer.
BACKGROUND OF THE INVENTION
Phosphorylation of tyrosine residues is a central feature of most
BACKGROUND OF THE INVENTION
Protein tyrosyl phosphorylation is an important cellular regulatory mechanism. Much work has implicated protein tyrosine kinases (PTKs) in the control of cell proliferation and differentiation. Many PTKs, when mutated and/or captured by retroviruses, can promote
FIELD OF INVENTION
This invention relates to methods and compositions for the diagnosis, classification, and treatment of cancer. More specifically, this invention is a method of identifying cancer using novel protein phosphorylation status.
BACKGROUND OF THE INVENTION
The intracellular tyrosine
BACKGROUND OF THE INVENTION
Many tumor cells depend on the activity of tyrosine kinases, which act, among other functions, to depress apoptosis in the cell. The tyrosine kinases are usually overproduced in malignant cells, which contributes to the cell's ability to resist apoptosis. Modulating the
BACKGROUND OF THE INVENTION
It is presently known that many human diseases are caused at least in part by proteins present in the cells of the afflicted individual. For example, certain proteins encoded by oncogenes are known to be responsible for the production of cancer in humans.
Included among
CROSS-REFERENCE TO RELATED APPLICATION
This application is a national stage filing under 35 U.S.C. .sctn.371 of international application PCT/SG2011/000293, filed Aug. 25, 2011, which was published under PCT Article 21(2) in English, and claims the benefit of Singapore Patent Application No.
TECHNICAL FIELD
The present invention concerns the technical field of the pharmaceutical industry.
In particular, the invention relates to compounds with tyrosine kinase inhibiting activity for use in the treatment of cancer in association with a defined dietetic regimen.
PRIOR ART
Molecularly
TECHNICAL FIELD
The present invention concerns the technical field of the pharmaceutical industry.
In particular, the invention relates to compounds with tyrosine kinase inhibiting activity for use in the treatment of cancer in association with a defined dietetic regimen.
PRIOR ART
Molecularly
FIELD OF THE INVENTION
This application relates to combination therapy for the treatment of cancer using inhibitors of heat shock protein 27 (Hasp 27) and an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) such as erlotinib, or antifolates such as pemetrexed.
BACKGROUND OF THE
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of International Application No. PCT/JP2011/080083 filed Dec. 26, 2011, claiming priority based on Japanese Patent Application No. 2010-290373 filed Dec. 27, 2010, the contents of all of which are incorporated herein by
TECHNICAL FIELD
This invention is directed to treatment of class I family of receptor tyrosine kinases overexpressing cancers.
BACKGROUND OF THE INVENTION
The class I family of receptor tyrosine kinases is described in Reese, M. D., et al, Stem Cells, 15, pages 1-8 (1997), the whole of which is
BACKGROUND OF THE INVENTION
The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.
The present invention relates to compounds and to the use of compounds in which the inhibition, regulation and/or